Thomas Ciulla MD PC

[ad_1] RT @OTEurope: How DME patients may fare differently in ‘real world’ versus trials https://t.co/37omb0jo7P https://t.co/mWVlEnaB0Q [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ViralKansaraPhD: I had the privilege of being a part of the research where my colleagues and I examined the “biofactory approach” in #G… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @RetinalPhys: Anti-VEGF Therapy in Macular Edema Due to Retinal Vein Occlusion: Real-world outcomes differ from those of clinical trials… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Just authored this @RetinalPhys​ article highlighting our #research on a leading cause of #vision loss. More effective and longer acting #treatments are needed! Retinal Physician – Anti-VEGF Therapy in Macular Edema Due to Retinal Vein Occlusion https://t.co/tR4b3mO078 [ad_2] Source by Thomas Ciulla, MD, MBA …

[ad_1] RT @ViralKansaraPhD: Excited to share the abstract on ocular #pharmacokinetics. Suprachoroidal delivery of this small molecule complement i… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Just published…Lean Six Sigma concepts can reduce waste and enhance patient care: Evolution of Primary Scleral Bucklin… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Our research was featured recently in Ophthalmology Times…. #retina #eyes #ophthalmology #ophthalmologist #optometry https://t.co/afuUqaz25c [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.